369 Clinical benefit of oral metronomic cyclophosphamide administration in heavily pretreated recurrent epithelial ovarian cancer | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Ovarian cancer

369 Clinical benefit of oral metronomic cyclophosphamide administration in heavily pretreated recurrent epithelial ovarian cancer

Free

Online download statistics by month:

Online download statistics by month: October 2021 to March 2023

	Abstract	Full	Pdf
Oct 2021	34	0	14
Nov 2021	32	0	7
Dec 2021	11	0	2
Jan 2022	26	0	2
Feb 2022	14	0	1
Mar 2022	11	0	5
Apr 2022	7	0	6
May 2022	17	0	13
Jun 2022	52	0	6
Jul 2022	20	0	3
Aug 2022	9	0	4
Sep 2022	10	0	5
Oct 2022	14	0	1
Nov 2022	18	0	1
Dec 2022	17	0	3
Jan 2023	25	0	3
Feb 2023	26	0	3
Mar 2023	8	0	1
Total	351	0	80